Miguel Forte
Chief Executive Officer at Bone Therapeutics
Meet Miguel Forte
“The development of vaccines for COVID-19 came about at lighting speed because of the alignment of a global need, regulatory support, and political will. Extensive scientific collaboration and focus to address a significant unmet medical need is an important lesson to extrapolate to the field of cell and gene therapies, where it is key to collaborate and combine emerging technologies to deliver what we know is bringing enormous value to patients with still unmanageable conditions.”
Forte believes the main challenge for the industry in 2021 is access. “The field explodes with enabling technologies but the objective should always be to deliver the value to patients.”
He is also excited about the increasing “professionalization” of biology: “Instead of cells learning ‘on the job,’ they will be administered already primed for tolerance, allogenicity, and for optimization of the therapeutic effect.”